Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012636 · ClinicalTrials.gov registry record · NA
Guidelines for Drug Therapy of Hypertension: Closing the Loop
A NA study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT00012636: Completed NA study, sponsored by US Department of Veterans Affairs.
NCT00012636 is a NA study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00012636, a NA study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
Hypertension is a major risk factor for heart disease and stroke. Evidence-based guidelines support the use of specific drugs for patients with specific comorbidities to maximize the decrease in cardiovascular risk; yet, many physicians do not follow these guidelines in choosing drug therapy.
Interventions
- PROCEDURE Computer generated statements about guideline concordance of drug therapy deliver to clinicians
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Est. Completion | 2000-09 |
| Phase | NA |
What the finished NCT00012636 record still lists
NCT00012636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Computer generated statements about guideline concordance of drug therapy deliver to clinicians is the first listed.
NCT00012636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00012636 about?
NCT00012636 is a clinical study titled "Guidelines for Drug Therapy of Hypertension: Closing the Loop". Hypertension is a major risk factor for heart disease and stroke. Evidence-based guidelines support the use of specific drugs for patients with specific comorbidities to maximize the decrease in cardiovascular risk; yet, many physicians do not follow these guidelines in choosing drug therapy.
What is the current status of trial NCT00012636?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00012636?
The interventions under investigation include: Computer generated statements about guideline concordance of drug therapy deliver to clinicians (PROCEDURE).
Who is sponsoring clinical trial NCT00012636?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00012636's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer